Market Research Logo

MediPoint: Infectious Disease Point of Care Testing - Global Analysis and Market Forecasts

MediPoint: Infectious Disease Point of Care Testing - Global Analysis and Market Forecasts

Summary

Point-of-care testing (POCT), as known as bedside/near-patient testing is one of the most rapidly growing areas in IVD.

Systems that are categorized as POC include the following -

  • Disposable systems or devices, which vary from reagent test strips for a single analyte to multi-analyte reagent strips
  • Small analyzers, usually hand-held devices
  • Desktop analyzers are larger and include systems designed for use in clinics or small laboratories.
The infectious disease POCT space represents one of the fastest growing markets within the POC space. Just under $700 million in annual global sales and growth rate of 7.7% during the forecast period; the US, India and Brazil, are expected to show the fastest growth.A number of factors, such as the increasing prevalence of infectious diseases in developing countries, the rising usage of home-based POC devices, the expansion of the test menu, and technological advancements in molecular testing and lab-on-chip technology are stimulating the demand for infectious disease POCT.The rate of infectious disease POCT adoption will be moderated by the requirement for regulatory compliance, the pressure to control cost, and the need to demonstrate the clear clinical-cost benefits of POCT over central laboratory testing.

Highlights

Key Questions Answered
  • What is the current and future infectious disease POCT market outlook in the developed and emerging markets? What trends are affecting the global market?
  • What is the competitive landscape and market share of major players in the infectious disease POCT space across different regions?
  • What are the key, high growth markets that IVD manufacturers should expand into? Which market segments are growing the fastest?
  • What are the unmet needs with the infectious disease POC tests currently on the market? How will emerging technologies such as molecular POC assays fulfil these unmet needs?
  • What are the key factors influencing a physician to use infectious disease POC tests? What is physician perception and market outlook of these devices?
  • What are the challenges and barriers that have hindered widespread adoption of infectious disease POC devices?
Scope
  • Competitive assessment: Currently marketed infectious disease POC products and evolving competitive landscape
  • In-depth analysis of unmet needs and adoption trends of different infectious disease POC devices
  • Insightful review of the key industry drivers, opportunities, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications
  • Pipeline analysis: Emerging products and technologies.
  • Annualized total infectious disease POCT market revenue by segment and market outlooks by country from 2013-2022.
  • Other key topics covered include strategic competitive assessment, market characterization, identification of unmet needs, market dynamics, and implications of the emerging technologies on the market.
Reasons to buy

The report will enable you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline
  • Develop business strategies by understanding the trends shaping and driving the global market
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global market in the future
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage
  • Track device sales in the global market from 2013-2022
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Industry Overview
3.1 Infectious Disease POCT Overview
3.2 Reimbursement Trends
3.2.1 US
3.2.2 France
3.2.3 Germany
3.2.4 Italy
3.2.5 Spain
3.2.6 UK
3.2.7 Japan
3.2.8 China
3.2.9 India
3.2.10 Brazil
3.3 Mergers, Acquisitions, and Key Partnerships
4 Unmet Needs
4.1 Multiplexing
4.2 Sensitivity of Infectious Disease Immunoassays
4.3 Analytical Performance
4.4 Data Recording and Management
4.5 Infectious Disease POCT to Curb Usage of Antibiotics
4.6 Cost-Effectiveness Data
4.7 Primary Care Physician Needs
5 Competitive Assessment
5.1 Company Share Analysis
5.1.1 Global
5.2 Alere
5.2.1 Overview
5.2.2 Marketed Products Assessment
5.2.3 SWOT Analysis
5.3 Beckman Coulter
5.3.1 Overview
5.3.2 Marketed Products Assessment
5.3.3 SWOT Analysis
5.4 BioMerieux
5.4.1 Overview
5.4.2 Marketed Products Assessment
5.4.3 SWOT Analysis
5.5 Cepheid
5.5.1 Overview
5.5.2 Marketed Products Assessment
5.5.3 SWOT Analysis
5.6 Chembio Diagnostics
5.6.1 Overview
5.6.2 Marketed Products Assessment
5.6.3 SWOT Analysis
5.7 Meridian Bioscience
5.7.1 Overview
5.7.2 Marketed Products Assessment
5.7.3 SWOT Analysis
5.8 OraSure Technologies
5.8.1 Overview
5.8.2 Marketed Products Assessment
5.8.3 SWOT Analysis
5.9 Quidel
5.9.1 Overview
5.9.2 Marketed Products Assessment
5.9.3 SWOT Analysis
5.10 Roche Diagnostics
5.10.1 Overview
5.10.2 Marketed Products Assessment
5.10.3 SWOT Analysis
5.11 Trinity Biotech
5.11.1 Overview
5.11.2 Marketed Products Assessment
5.11.3 SWOT Analysis
5.12 Other Companies
5.12.1 North American Market Companies
5.12.2 European Market Companies
5.12.3 APAC and Other Markets Companies
6 Pipeline Assessment
6.1 Overview
6.2 Early Development Pipeline
6.3 Pre-clinical Stage Pipeline
6.4 Clinical Stage Pipeline
6.5 Products in the Approval Process
7 Market Outlook
7.1 Test Trends
7.1.1 HIV POCT
7.1.2 Influenza POCT
7.1.3 HBV POCT
7.1.4 HCV POCT
7.1.5 C. difficile POCT
7.2 Market Dynamics
7.2.1 Driver: Fast Turnaround Time
7.2.2 Driver: Emergence of Molecular Infectious Disease POCT
7.2.3 Driver: Expansion POCT Menu
7.2.4 Driver: CLIA-Waived Status for POCT
7.2.5 Driver: Rising Prevalence of Diseases
7.2.6 Barriers: Management of POCT
7.2.7 Barriers: Competition with Laboratory Tests
7.2.8 Barriers: Reimbursement
7.2.9 Barriers: Regulatory Compliance
7.3 Market Outlook By Market Segment
7.3.1 Global Overview
7.3.2 HIV POCT
7.3.3 Influenza POCT
7.3.4 HBV POCT
7.3.5 HCV POCT
7.3.6 C. difficile POCT
7.3.7 Molecular POCT Analyzers
7.4 Market Outlook By Geography
7.4.1 Global Overview
7.4.2 US
7.4.3 France
7.4.4 Germany
7.4.5 Italy
7.4.6 Spain
7.4.7 UK
7.4.8 Japan
7.4.9 China
7.4.10 India
7.4.11 Brazil
8 Appendix
8.1 Bibliography
8.2 Abbreviations
8.3 Report Methodology
8.3.1 Overview
8.3.2 Coverage
8.3.3 Secondary Research
8.3.4 Forecasting Methodology
8.3.5 Primary Research - Key Opinion Leader Interviews
8.3.6 Primary Research - Physician and Industry Interviews
8.3.7 Expert Panel Validation
8.4 About the Team
8.4.1 Analysts
8.4.2 Tyler Fletcher, Global Head of Medical Devices
8.5 About MediPoint
8.6 About GlobalData
8.7 Disclaimer
1.1 List of Tables
Table 1: Advantages and Disadvantages of POCT
Table 2: Medicare National Average of Clinical Laboratory Services Reimbursement for Infectious Disease Testing, 2014-2015
Table 3: Mergers, Acquisitions, and Key Partnerships, 2014-2016
Table 4: Company Profile - Alere
Table 5: Alere Infectious Disease POCT Portfolio Assessment, 2016
Table 6: SWOT Analysis - Alere
Table 7: Company Profile - Beckman Coulter
Table 8: Beckman Coulter Infectious Disease POCT Portfolio Assessment, 2016
Table 9: SWOT Analysis - Beckman Coulter
Table 10: Company Profile - BioMerieux
Table 11: BioMerieux’s Infectious Disease POCT Portfolio Assessment, 2016
Table 12: SWOT Analysis - BioMerieux
Table 13: Company Profile - Cepheid
Table 14: Cepheid’s Infectious Disease POCT Portfolio Assessment, 2016
Table 15: SWOT Analysis - Cepheid
Table 16: Company Profile - Chembio Diagnostics
Table 17: Chembio Diagnostics’ Infectious Disease POCT Portfolio Assessment, 2016
Table 18: SWOT Analysis - Chembio Diagnostics
Table 19: Company Profile - Meridian Bioscience
Table 20: Meridian Bioscience’s Infectious Disease POCT Portfolio Assessment, 2016
Table 21: SWOT Analysis - Meridian Bioscience
Table 22: Company Profile - OraSure Technologies
Table 23: OraSure Technologies’ Infectious Disease POCT Portfolio Assessment, 2016
Table 24: SWOT Analysis - OraSure Technologies
Table 25: Company Profile - Quidel
Table 26: Quidel’s Infectious Disease POCT Portfolio Assessment, 2016
Table 27: SWOT Analysis - Quidel
Table 28: Company Profile - Roche Diagnostics
Table 29: Roche Diagnostics’ Infectious Disease POCT Portfolio Assessment, 2016
Table 30: SWOT Analysis - Roche Diagnostics
Table 31: Company Profile - Trinity Biotech
Table 32: Trinity Biotech’s Infectious Disease POCT Portfolio Assessment, 2016
Table 33: SWOT Analysis - Trinity Biotech
Table 34: Other Infectious Disease POCT Companies in North America, 2016
Table 35: Other Infectious Disease POCT Companies in Europe, 2016
Table 36: Other Infectious Disease POCT Companies in APAC and Other Regions, 2016
Table 37: Key Infectious Disease POCT Products in Early Development, 2016
Table 38: Key Infectious Disease POCT Products in Pre-clinical Stage, 2016
Table 39: Key Infectious Disease POCT Products in the Clinical Stage, 2016
Table 40: Key Infectious Disease POCT Pipelines in Approval Process, 2016
Table 41: Global HIV POCT Volume Forecast (thousands) by Region, 2013-2022
Table 42: Global Influenza POCT Volume Forecast (Thousands) by Region, 2013-2022
Table 43: Global HBV POCT Volume Forecast (Thousands) by Region, 2013-2022
Table 44: Global HCV POCT Volume Forecast (Thousands) by Region, 2013-2022
Table 45: Global C. difficile POCT Volume Forecast (Thousands) by Region, 2013-2022
Table 46: Global Infectious Disease POCT Sales Forecast ($m) by Market Segment, 2013-2022
Table 47: HIV POCT Sales Forecast ($m), 2013-2022
Table 48: Influenza POCT Sales Forecast ($m), 2013-2022
Table 49: HBV POCT Sales Forecast ($m), 2013-2022
Table 50: HCV POCT Sales Forecast ($m), 2013-2022
Table 51: C. difficile POCT Sales Forecast ($m), 2013-2022
Table 52: Molecular POCT Analyzers Sales Forecast ($m), 2013-2022
Table 53: Global Infectious Disease POCT Sales Forecast ($m) by Country, 2013-2022
Table 54: US Infectious Disease POCT Sales Forecast ($m), 2013-2022
Table 55: France Infectious Disease POCT Sales Forecast ($m), 2013-2022
Table 56: Germany Infectious Disease POCT Sales Forecast ($m), 2013-2022
Table 57: Italy Infectious Disease POCT Sales Forecast ($m), 2013-2022
Table 58: Spain Infectious Disease POCT Sales Forecast ($m), 2013-2022
Table 59: UK Infectious Disease POCT Sales Forecast ($m), 2013-2022
Table 60: Japan Infectious Disease POCT Sales Forecast ($m), 2013-2022
Table 61: China Infectious Disease POCT Sales Forecast ($m), 2013-2022
Table 62: India Infectious Disease POCT Sales Forecast ($m), 2013-2022
Table 63: Brazil Infectious Disease POCT Sales Forecast ($m), 2013-2022
1.2 List of Figures
Figure 1: Global Infectious Disease POCT Market, by Company Share, 2015
Figure 2: Infectious Disease POCT Pipelines, by Stage of Development, 2016
Figure 3: Global HIV POCT Volume Forecast (Thousands) by Region, 2013-2022
Figure 4: Global Influenza POCT Volume Forecast (Thousands) by Region, 2013-2022
Figure 5: Global HBV POCT Volume Forecast (Thousands) by Region, 2013-2022
Figure 6: Global HCV POCT Volume Forecast (Thousands) by Region, 2013-2022
Figure 7: Global C. difficile POCT Volume Forecast (Thousands) by Region, 2013-2022
Figure 8: Global Infectious Disease POCT Sales Forecast ($m) by Market Segment, 2013-2022
Figure 9: Global Infectious Disease POCT Market Share Forecast ($m) by Segment, 2015 and 2022
Figure 10: HIV POCT Sales Forecast ($m), 2013-2022
Figure 11: Influenza POCT Sales Forecast ($m), 2013-2022
Figure 12: HBV POCT Sales Forecast ($m), 2013-2022
Figure 13: HCV POCT Sales Forecast ($m), 2013-2022
Figure 14: C. difficile POCT Sales Forecast ($m), 2013-2022
Figure 15: Molecular POCT Analyzers Sales Forecast ($m), 2013-2022
Figure 16: Global Infectious Disease POCT Sales Forecast ($m), 2013-2022
Figure 17: Global Infectious Disease POCT Market Share Forecast ($m) by Country, 2015 and 2022
Figure 18: US Infectious Disease POCT Sales Forecast ($m), 2013-2022
Figure 19: US Infectious Disease POCT Market Share Forecast (%) by Segment, 2015 and 2022
Figure 20: France Infectious Disease POCT Sales Forecast ($m), 2013-2022
Figure 21: France Infectious Disease POCT Market Share Forecast (%) by Segment, 2015 and 2022
Figure 22: Germany Infectious Disease POCT Sales Forecast ($m), 2013-2022
Figure 23: Germany Infectious Disease POCT Market Share Forecast (%) by Segment, 2015 and 2022
Figure 24: Italy Infectious Disease POCT Sales Forecast ($m), 2013-2022
Figure 25: Italy Infectious Disease POCT Market Share Forecast (%) by Segment, 2015 and 2022
Figure 26: Spain Infectious Disease POCT Sales Forecast ($m), 2013-2022
Figure 27: Spain Infectious Disease POCT Market Share Forecast (%) by Segment, 2015 and 2022
Figure 28: UK Infectious Disease POCT Sales Forecast ($m), 2013-2022
Figure 29: UK Infectious Disease POCT Market Share Forecast (%) by Segment, 2015 and 2022
Figure 30: Japan Infectious Disease POCT Sales Forecast ($m), 2013-2022
Figure 31: Japan Infectious Disease POCT Market Share Forecast (%) by Segment, 2015 and 2022
Figure 32: China Infectious Disease POCT Sales Forecast ($m), 2013-2022
Figure 33: China Infectious Disease POCT Market Share Forecast (%) by Segment, 2015 and 2022
Figure 34: India Infectious Disease POCT Sales Forecast ($m), 2013-2022
Figure 35: India Infectious Disease POCT Market Share Forecast (%) by Segment, 2015 and 2022
Figure 36: Brazil Infectious Disease POCT Sales Forecast ($m), 2013-2022
Figure 37: Brazil Infectious Disease POCT Market Share Forecast (%) by Segment, 2015 and 2022
Figure 38: Infectious Disease POCT - Physician Survey Count by Country (N=121)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report